Form 4: Zura Bio CEO Robert Lisicki Reports Stock Option Grant
SEC Form 4 Filing
Zura Bio Ltd's CEO, Robert Lisicki, reports the acquisition of stock options for 1,153,000 Class A Ordinary Shares.
Summary
- Robert Lisicki, CEO of Zura Bio Ltd, filed a Form 4 with the SEC.
- The filing reports the grant of an employee share option to Lisicki on February 27, 2025, for 1,153,000 Class A Ordinary Shares at an exercise price of $1.20.
- The options vest over time, starting with one-fourth on February 27, 2026, and the remainder in equal quarterly installments thereafter, contingent upon continuous service.
- Lisicki also granted power of attorney to Kim Davis and Lindsey McClelland of Zura Bio Limited to execute Forms 3, 4, and 5 on his behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the CEO.
Future Outlook
The vesting schedule suggests an expectation of continued service and contribution from the CEO over the next several years.
Industry Context
Stock option grants are a common form of executive compensation in the biotech industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules, such as the one described, are typical for incentivizing long-term performance.
- Comparable companies often use similar equity-based compensation to attract and retain key personnel.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to drive long-term value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of the earliest transaction (grant of stock options). |
| 02/27/2026 | First vesting date for the stock options (one-fourth of the shares). |
| 02/27/2035 | Expiration date of the stock options. |
| 03/03/2025 | Date of signature for the Form 4 and Power of Attorney. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.